introduction Lymphoblastic lymphomas (LBL) are lymphoid malignancies from immature or precursor cells representing one third of the cases of non-Hodgkin lymphoma (NHL) in children and adolescents. [1] [2] [3] The current World Health Organization (WHO) classification assigns tumours of hematopoietic and lymphoid tissues in T lymphoblastic leukemia/lymphoma and B lymphoblastic leukemia/ lymphoma. 4, 5 Of note, only approximately 10% of LBL express B-cell markers in contrast to approximately 85% of acute lymphoblastic leukemia (ALL). 6 The distinction between leukemia and lymphoma is arbitrary and based on the extent of involvement of bone marrow (BM). It is usual to diagnose patients with ≥ 25% lymphoblasts in BM as having ALL, whereas patients with extra-medullary disease and less than 25% blasts in BM are diagnosed as LBL. 7, 8 Clinical presentation varies according to immunophenotype. T-cell lymphoblastic lymphomas (T-LBL) most commonly involve the anterior mediastinum and supradiaphragmatic lymph nodes. 2, 9 Pre-B lymphoblastic lym-phomas (pB-LBL) are usually localized in peripheral lymph nodes and extranodal sites, such as skin, soft tissues, and bone, with a preference for the head and neck regions. 10, 11 Whether LBL and ALL in childhood are biologically identical or rather distinct disorders is not entirely clear. 12, 13 To date, the pathogenesis and genetic changes of LBL is poorly understood. 3 LBLs are most effectively treated using ALL-based therapies.
14 Nowadays, event-free survival (EFS) can be reached by 75-90% of children and adolescents. 3, 15, 16 The objective of this study was to contribute to the knowledge of the clinical course and treatment outcome of 27 children and adolescents with LBL followed up at a single tertiary center.
Methods
This is a longitudinal retrospective observational cohort study that evaluated 27 children and adolescents aged 16 years or less with LBL. The patients were admitted to the Pediatric Hematology Unit, University Hospital, Universidade Federal de Minas Gerais (UFMG), between January 1981 and December 2013. Seven patients were excluded from the Kaplan-Meier survival analysis (see statistical session) because of previous treatment at other institutions (n=3), severe concomitant immunodeficiency (one with primary and two with secondary immunodeficiency), and one with bone marrow involvement with atypical cells that were not considered lymphoblasts.
Medical records were reviewed to collect demographic data (age, gender), clinical data (medical history, physical examination, clinical presentation), diagnostic procedures (imaging studies, bone marrow aspiration, cerebrospinal fluid [CSF] analysis), staging, laboratory data (lactate dehydrogenase [LDH] levels, blood counts, serum electrolytes, liver and kidney tests), treatment, and outcome. Diagnosis was made by incisional or excisional biopsy, or cytological examination of pleural or abdominal effusions. Karyotype studies were not available at the time. All the diagnoses were confirmed by morphological and immunohistochemistry criteria defined by the World Health Organization (WHO) classification. 17 Immunohistochemistry was performed using monoclonal antibodies CD20, CD10, CD79a, CD30, CD3, CD15, TdT, CD45, and CD45RO for the detection of B and T cells. Cell lineage assignment required 50% or more of positive neoplastic B or T cells. Pleural or abdominal effusions were examined by flow cytometry.
Clinical staging was based on the St. Jude Children's Research Hospital staging system. 18 Central nervous system (CNS) disease was diagnosed by the presence of morphologically identifiable lymphoma cells (regardless of quantity) in CSF, an intracranial mass or cranial nerve palsy not caused by an extradural mass.
Treatment
Patients with LBL were treated according to protocols based on an ALL-type strategy. Patients admitted between 1981 and 1987 were treated according to the modified LSA2L2 protocol of the Memorial Sloan-Kettering Cancer Center. 19 After 1987, patients were treated with a BFM-83-based protocol (Berlin-Frankfurt-Münster). 20 Response criteria Complete remission (CR) was defined as the disappearance of all tumor masses confirmed by clinical examination and imaging investigations, one month after therapy. After the end of treatment, the patients were followed at 30-day intervals during the first year, at 60-day intervals during the second year and at 3-to 6-month intervals up to five years. Progression of the local tumor was defined if the tumor site showed no decrease in size after starting chemotherapy. Relapse was defined as the recurrence of lymphoma with the same histological or immunophenotypic features as the initial one at any site after CR was achieved. Local relapse was diagnosed when it involved a previously involved site (except bone marrow and CSF).
Statistical analysis
The time limit for the current study was the end of December 2013. Data are reported as medians and interquartile range (IQ) or means and standard deviation (SD), when appropriate. Mann-Whitney or Kruskal-Wallis tests were used to compare nonparametric continuous variables. Dichotomous variables were compared using two-tailed chisquare test or Fisher exact test. Overall survival (OS) was defined as the time from diagnosis to date of death due to any cause or date of last follow-up contact for patients who were alive. The OS was analyzed using the KaplanMeier method for 20 patients, as mentioned before.
Ethical issues
The study was approved by the Research Ethics Committee of UFMG. Written informed consent was obtained from the guardians of the patients and, when appropriate, from the patients themselves, according to the Helsinki Declaration.
results

Patient characteristics
The median age at diagnosis was 11.6 years (interquartile: 4.6-13.8 years). It was 6.1 years for patients with pB-LBL and 13.2 for those with T-LBL. There was a predominance of males (1.6:1). Diagnosis was based on cytological examination of pleural effusions in two patients (7%), and on tumor biopsies for the remaining cases. Immunohistochemistry was performed in 21 patients and immunophenotyping in two patients. Immunohistochemistry was inconclusive in six patients due to technical problems with the fixing of samples. The clinical and demographic characteristics of the patients are shown in Table 1 . LBLs were of T-precursor cell origin in the majority of cases (16 patients-59%). The most common manifestation at diagnosis in T-cell cases was mediastinal enlargement, observed in nine patients, followed by lymph nodes in six. Intra-abdominal tumor was the major site of involvement in patients with pB-LBL, observed in three cases followed nodal disease in two cases. A paravertebral tumor was the initial manifestation in one patient who had a secondary immunodeficiency. Most patients had advanced disease (67%). Serum LDH concentration immediately at diagnosis was available only in 16 cases and the mean concentration was 831.63 IU/L (range: 152 to 3,897 IU/L). Serum uric acid was available for 22 patients with a mean value of 4.3 mg/dL (range: 2.0 to 8.5 mg/dL). (Figure 1 ).
discussion
LBLs comprise approximately 30% of the NHLs that occur in children and young adults. The vast majority of them arise from immature T-cells, corresponding to defined stages of thymocyte differentiation, and approximately 10 to 15% are precursor B-cell lymphomas.
2,15,21
LBL accounted for 23% of cases of NHL enrolled in our institution in the period of 26 years. Burkitt's lymphoma is the leading subtype in our institution. 22 In agreement with the literature, the most frequent phenotype among our patients had T-cell origin. Approximately 20% were of pB-cell origin, and the remaining cases were unclassified. In a Brazilian epidemiologic study, LBL represented 36% of all NHLs (272 cases). T-cell phenotype was the most prevalent representing 60% of cases; 25% were of the pB-cell phenotype, and the remaining 15% were unclassified. 23 Patients with pB-LBL were younger than those with T-LBL, as reported by others (15, 24) . However, the median age at diagnosis for our patients with T-LBL was a little higher than reported before (around 8.8 years old). 24 As also reported in previous studies, there was a clear predominance of males (2:1).
Presenting clinical features for T-LBL are quite distinct from those for pB-LBL. Mediastinal, bone marrow (BM) and central nervous system (CNS) involvements are pared with boys might have contributed to worst treatment results for females with increasing age. 24 In general, the outcome is worst for CNS-positive as compared with CNS-negative patients, although not for all NHL subgroups. CNS involvement occurs more frequently in patients with advanced disease. In contrast to patients with Burkitt's lymphoma, CNS involvement does not negatively impact treatment results for LBL patients. 29 Over 80% of patients with T-LBL do not have marrow involvement at diagnosis by morphologic examination of bilateral marrow aspirates and biopsies. 2 However, in a series of 99 children with T-LBL, more than two thirds of them had neoplastic lymphoblasts detected by flow cytometry. This finding implies that a more sensitive method for investigating neoplastic cells in the BM at diagnosis may contribute to a more appropriate risk classification. 30 Persistent minimal disease during and/or at the end of induction therapy may also identify a poor risk group of patients. 30 In relation to stage, patients with localized disease have a good prognosis. 31 Disease stage was a major prognostic factor for children with pB-LBL, with significant better overall survival and event-free survival rates observed in patients with stage I to III as compared to those with stage IV. 21 In the present study, out of five patients who died, four had disseminated disease. The fifth patient had localized disease and primary immunodeficiency. predominant in T-LBL. 25 In the present study, mediastinal enlargement was present in more than half of the cases. Two patients had BM invasion, but CNS disease was not observed. The clinical presentation of children with pB-LBL varies considerably. Bone, soft tissue, and visceral organs can all be involved. In a series of twenty-seven patients with pB-LBL, the majority of them had nodal disease. 15 In the present study, although there were only six patients, five had intra-abdominal or lymph nodal disease as the presenting clinical manifestation.
T-LBL stage is often advanced at diagnosis (stage III--IV), unlike pB-cell LBL, which primarily is a localized disease. 26, 27 These results are coincident with those observed in our series. The majority of patients were diagnosed with advanced stages of disease.
Prognostic markers in LBL are yet to be clearly defined. Age, gender, response to treatment, stage, molecular prognostic markers, and marrow and CNS involvement remain unclear as prognostic factors in LBL. For instance, in a series of 85 children and adolescents with advanced LBL the multivariate analysis failed to demonstrate age, gender, lactate dehydrogenase level, and marrow or central nervous system disease to have independent prognostic value. 28 In a recent study by Burkhardt, adolescent females with T-LBL had a worse outcome. The worst outcome of girls compared with boys observed only in patients older than 9 years arose the issue whether the advanced pubertal changes of girls com- No single recurrent chromosome abnormality has been identified as characteristic of LBL. 31 Recently, activating NOTCH1 mutations (chromosome 9) were reported to be associated with favorable prognosis. Loss of heterozygosity at chromosome 6q (LOH6q) was reported to be associated with increased relapse risk for patients with T-LBL. 26 Response to treatment has been considered an important prognostic factor. In a series of 121 children with T-LBL, the ones who had reached CR on the seventh day of chemotherapy (prephase) had a better prognosis than those who had not reached CR. 9 Because of its biological relationship to ALL, patients with LBL have been treated with therapeutic protocols used for ALL, which are based on the principle of continual exposure to cytostatics over a long period of time. 32 Among our patients this strategy also proved highly efficacious. Only two patients relapsed (7.4%), and both died. As reported in modern treatment protocols for LBL, 10% of patients with progressive disease or relapse have indeed an extremely poor prognosis. 1 The probability of 5-year survival for 20 patients with de novo LBL and similarly treated was almost 80%, similar to those achieved in major treatment centers (75 to 90%). 3 
conclusion
Our findings confirm a favorable prognosis for children with LBL treated with ALL-based therapies. The subtle differences between LBL and ALL are elusive, and have raised questions as to whether identical therapeutic approaches are warranted for each immunophenotypic category. Prognostic markers in LBL have also yet to be clearly defined. The outcome for patients with recurrent disease is poor. Molecular and cellular pathogenesis of malignant transformation to LBL is still a challenge to be tackled in order to develop strategies for prevention, early identification, and targeted therapies. 4, [6] [7] [8] [9] [10] [11] [12] [13] 8) . LL de células T foi identificado em 16 pacientes (59%) e a manifestação primária mais comum foi o acometimento mediastinal em 9 pacientes (56%). Tumor intra-abdominal foi a manifestação clínica principal nos pacientes com LL de células pré-B. A maioria dos pacientes apresentava doença avançada (18 pacientes -67%) ao diagnóstico. Vinte e quatro pacientes (89%) alcançaram remissão clínica completa. Após um período de acompanhamento médio de 43 meses (intervalo interquartil, 6,4-95), 22 pacientes (81%) continuam vivos em primeira remissão clínica completa. Cinco crianças (18,5%) morreram, três delas logo após a admissão e duas após recidiva. A probabilidade de sobrevida em cinco anos para 20 pacientes com LL de novo foi de 78% (SD 9.4). Conclusão: nossos resultados confirmam o prognóstico favorável de crianças com LL tratadas com regime de quimioterapia intensiva derivado da terapia de LLA.
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